Dietmar Berger, M.D., Ph.D., joined Gilead Sciences as chief medical of | Dietmar Berger became Gilead Sciences’ new chief ...

"I am also pleased to report that the cash runway now extends into 2028 with the re-allocation of resources to our therapeutics pipeline." Recent Corporate Highlights Arcturus is advancing ...

The strategic partnership is likely to diversify CRISPR Therapeutics’ pipeline by adding Sirius’s lead candidate, SRSD107, a next-generation, long-acting siRNA therapy, which is being ...

What potential does the company’s pipeline hold for addressing unmet medical needs? Contineum Therapeutics’ pipeline holds significant potential for addressing unmet medical needs across ...

It also covers the Hunter Syndrome pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this ...

Cullinan Therapeutics (NASDAQ:CGEM) signed a deal with Genrix Bio for an exclusive license for velinotamig, a bispecific T ...

This financial profile underscores the company’s continued investment in its pipeline and the challenges inherent in bringing novel therapies to market. PTC Therapeutics’ pipeline is diverse ...

“I am also pleased to report that the cash runway now extends into 2028 with the re-allocation of resources to our therapeutics pipeline.” The Company recently completed the recruitment of 212 ...

Fate Therapeutics FATE reported a loss of 32 cents ... Its immuno-oncology pipeline includes iPSC-derived natural killer (NK) cells and T-cell product candidates. A phase I study of FT819, a ...